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Abstract
Objectives: Increased arterial stiffness is an independent predictor of 
death from cardiovascular disease, and cardiovascular disease is the lead-
ing cause of death among patients with end-stage renal disease. The aim 
of this study was to compare arterial stiffness in hemodialysis patients.
Patients and Methods: Serum samples were taken from 42 hemodialy-
sis patients with the same high flux artificial kidney. Brachial-ankle pulse 
wave velocity (baPWV) was measured in the right or left brachial artery 
to the ankle segments that did not have arteriovenous fistula using an 
automatic pulse wave analyzer. Plasma adiponectin levels were measured 
using a commercial enzyme-linked immunosorbent assay kit. Body fat 
mass was determined using bioelectrical impedance analysis.
Results: Arterial stiffness was higher in hemodialysis patients (85.7%). 
Age (p = 0.018), systolic blood pressure (p < 0.001) and fasting glucose 
(p = 0.007) were higher, and hematocrit (p = 0.016) was lower in hemo-
dialysis patients with arterial stiffness. Plasma homocystine (p = 0.899), 
adiponectin (p = 0.204), C-reactive protein (p = 0.276), body fat mass 
(p = 0.756), total cholesterol (p = 0.607), triglyceride (p = 0.737), calcium 
(p = 0.698) and phosphorous (p = 0.629) metabolism were not associated 
with arterial stiffness in hemodialysis patients. Multivariate forward step-
wise linear regression analysis of arterial stiffness showed that systolic 
blood pressure and age were independent predictors of arterial stiffness 
in hemodialysis patients and explained 45.8% of the variance in patients 
with arterial stiffness (R2 = 0.458).
Conclusion: The incidence of arterial stiffness was higher in hemodialy-
sis patients. Systolic blood pressure and age were independent predictors 
of arterial stiffness in hemodialysis patients. [Tzu Chi Med J 2007;19(3):
139–144]
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1. Introduction
Cardiovascular disease is the leading cause of death 
among patients with end-stage renal disease (ESRD) 
[1]. Moreover, arterial stiffness has been associated 
with a high incidence of cardiovascular events and 
death in patients with ESRD [2,3]. The high incidence 
of cardiovascular disease in ESRD has been ascribed to 
an excess of traditional risk factors including hyperten-
sion, dyslipidemia, smoking, old age, diabetes and non-
traditional risk factors including hyperhomocysteinemia, 
increased C-reactive protein (CRP), abnormal calcium 
and/or phosphorous metabolism [4]. Clinical studies 
have shown that damage of arteries is a major con-
tributory factor to death in patients with uremia [5,6]. 
Brachial-ankle pulse wave velocity (baPWV) is a nonin-
vasive method for analyzing vascular stiffness in the 
assessment of vascular damage [7,8]. The validity and 
reproducibility of baPWV measurements are consider-
ably high, and this method seems to be an acceptable 
marker reflecting arteriosclerosis [8,9]. High baPWV is 
also found to be a risk factor for carotid atherosclero-
sis in patients with ESRD [10]. The aim of this study 
was to investigate the risk factors of arterial stiffness 
among hemodialysis patients in eastern Taiwan.
2. Patients and methods
2.1. Patients
Forty-two hemodialysis patients with the same high 
flux disposable artificial kidney (Fx class; Fresenius, 
Bad Homburg, Germany), including 27 men and 15 
women aged from 26 to 87 years, were studied in 
April 2005 in a medical center in Hualien, eastern 
Taiwan. Hemodialysis was performed three times a 
week (4 hours/day) using standard bicarbonate dia-
lysate. The Protection of Human Subjects Institutional 
Review Board at Tzu Chi University and Hospital 
approved this study. Anthropometric measurements 
included height and weight measurements. The Kt/V 
and urea reduction ratio (URR) were measured before 
dialysis, and immediately after dialysis blood urea 
nitrogen (BUN) levels were measured using a formal 
single-compartment dialysis urea kinetic model.
2.2. Bioimpedance analysis 
Impedance measurements were performed at the bed-
side according to the standard, tetrapolar, whole body 
(hand-foot) technique, using a single-frequency (50-kHz) 
analyzer (Biodynamic-450; Biodynamics Corporation, 
Seattle, WA, USA). Measurements were carried out by 
the same operator 20 minutes before dialysis began. 
Fat mass was collected and analyzed using the specific 
formulae offered by the manufacturer.
2.3. Evaluation of baPWV
Arterial stiffness was assessed using baPWV in the right 
or left brachial artery at the ankle segments that did 
not have arteriovenous fistula. The device measures 
baPWV using an oscillometric method [11]. Complete 
measurement of all baPWV was usually finished in 
less than 5 minutes. The baPWV was automatically 
calculated using a waveform analyzer (VP-1000; Colin 
Corporation, Komaki, Japan). The baPWV value of 
13.5 m/s was defined as the threshold value for arterial 
stiffness according to the manufacturer’s definition.
2.4. Biochemical investigations
Fasting serum samples taken before dialysis from each 
subject were immediately centrifuged for biochemi-
cal study. Blood samples of approximately 0.5 mL for 
complete blood count (CBC) (Vitros 750; Johnson & 
Johnson, USA) and others were immediately centri-
fuged at 3000 rpm for 10 minutes. The plasma was 
stored at 4°C for biochemical examinations within 
1 hour after collection. Plasma levels of BUN, creati-
nine, fasting glucose, total cholesterol, triglyceride, 
calcium, phosphorus, albumin, homocysteine and 
CRP were measured using an autoanalyzer (Hitachi 
747; Hitachi, Tokyo, Japan) to evaluate various bio-
chemical data. The serum hepatitis B surface antigen 
(HBsAg) and antibodies to hepatitis C virus (anti-HCV) 
were detected using commercially available enzyme 
immunoassays (Abbott Laboratories, Abbott Park, 
IL, USA). Plasma adiponectin levels were measured 
using a commercial enzyme-linked immunosorbent 
assay kit (Linco Research Inc., St Charles, MO, USA).
2.5. Statistical analysis
Data are expressed as case numbers and analyzed 
using the χ2 test. Other data are expressed as 
mean ± standard deviation and compared using the 
Student t test. A p value less than 0.05 was con-
sidered statistically significant. All statistically sig-
nificant variables (p < 0.05) were put into a multiple 
linear regression model as independent variables 
and we used baPWV as a dependent variable. Data 
were analyzed using SPSS version 11.0 (SPSS Inc., 
Chicago, IL, USA) for Windows.
3. Results
The basic clinical characteristics of hemodialysis 
patients are presented in Table 1. Twenty-seven men 
and 15 women were enrolled in this study. Thirty 
patients were aged below 65 years. The causes of ure-
mia varied. Eighteen patients suffered from uremia 
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due to diabetes mellitus, 10 of them were due to 
hypertension and 10 were due to chronic glomeru-
lonephritis. The percentage of patients who had 
been on hemodialysis for less than 5 years was 57%, 
whereas 14% had been on hemodialysis for more 
than 10 years.
Patients were divided into arterial stiffness and 
non-arterial stiffness groups based on the results of 
baPWV. The characteristics of each group are pre-
sented in Table 2 and Table 3. Thirty-six patients 
(85.7%) had arterial stiffness and six patients (14.3%) 
did not have arterial stiffness. Age (p = 0.018), systolic 
blood pressure (p < 0.001) and fasting glucose 
(p = 0.007) were higher, and hematocrit (p = 0.016) 
was lower in hemodialysis patients with arterial stiff-
ness. There were no statistically significant differ-
ences in height, weight, smoking, betel nut chewing, 
Table 1 — Baseline clinical characteristics of hemo- 
dialysis patients in the study
 %
Sex
 Male 64
 Female 36
Age (yr)
 < 65 71
 ≥ 65 29
Cause of end-stage renal disease
 Diabetes 43
 Hypertension 24
 Glomerulonephritis 24
 Other  9
Duration of hemodialysis
 < 5 yr 57
 ≥ 5 yr and < 10 yr 29
 ≥ 10 yr 14
Table 2 — Comparisons of clinical background of hemo-
dialysis patients with and without arterial stiffness
 Non-arterial  Arterial 
 stiffness stiffness p
 n (%) n (%)
HBsAg   0.150
 Negative 6 (100) 30 (83.3)
 Positive 0 (0)   6 (16.7)
Anti-HCV   0.150
 Negative 6 (100) 30 (83.3)
 Positive 0 (0)   6 (16.7)
Gender    0.438
 Male 3 (50.0) 24 (66.7)
 Female 3 (50.0) 12 (33.3)
Smoking   0.097
 No 6 (100) 28 (77.8)
 Yes 0 (0)   8 (22.2)
Alcohol consumption   0.383
 No 5 (83.3) 34 (94.4)
 Yes 1 (16.7)   2 (5.6)
Betel nut chewing   0.383
 No 5 (83.3) 34 (94.4)
 Yes 1 (16.7)   2 (5.6)
Diabetes mellitus   0.410
 No 5 (83) 19 (53)
 Yes 1 (17) 17 (47)
Table 3 — Comparisons of laboratory parameters of hemodialysis patients with and without arterial stiffness*
 Non-arterial stiffness (n = 6) Arterial stiffness (n = 36) p
Age (yr) 43.00 ± 10.60 57.39 ± 13.49 0.018†
Duration of HD (mo) 73.00 ± 64.33 49.81 ± 45.54 0.283
Body weight (kg), pre-HD 61.77 ± 13.21 65.87 ± 12.98 0.484
Body weight (kg), post-HD 58.22 ± 12.31 62.72 ± 12.07 0.410
Height (cm) 163.15 ± 7.59 161.77 ± 9.28 0.734
Body fat mass, pre-HD 26.76 ± 6.88 27.78 ± 7.37 0.756
SBP (mmHg) 113.50 ± 13.58 154.80 ± 23.49 0.000†
DBP (mmHg) 71.67 ± 7.84 82.11 ± 15.18 0.110
WBC (×1000/μL) 6.33 ± 2.59 6.29 ± 1.89 0.962
Hct (%) 33.13 ± 4.34 29.76 ± 2.83 0.016†
CRP (mg/dL) 0.896 ± 0.911 0.438 ± 0.325 0.276
Homocysteine (μmol/L) 22.07 ± 7.44 22.52 ± 7.90 0.899
Adiponectin (ng/mL) 264.15 ± 25.74 277.204 ± 22.493 0.204
Triglyceride (mg/dL) 209.83 ± 197.30 180.75 ± 96.81 0.737
Cholesterol (mg/dL) 185.0 ± 49.7 174.89 ± 43.41 0.607
Fasting glucose (mg/dL) 115.67 ± 20.49 167.22 ± 95.45 0.007†
Creatinine (mg/dL) 12.75 ± 1.8 11.16 ± 2.25 0.109
Collected calcium (mg/dL) 9.1967 ± 0.428 9.33 ± 0.78 0.698
Phosphorus (mg/dL) 5.5 ± 2.2 5.15 ± 1.53 0.629
Calcium × phosphorus 50.28 ± 18.99 48.15 ± 15.72 0.766
IPH (pg/mL) 314.15 ± 239.60 206.76 ± 136.95 0.174
URR 0.67 ± 0.168 0.698 ± 0.074 0.695
Kt/V (Gotch) 1.208 ± 0.474 1.232 ± 0.261 0.910
*Data are expressed as mean ± standard deviation; †p < 0.05, malnourished vs. well-nourished patients, Student t test. HD = hemodialysis; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; WBC = white blood cell count; Hct = hematocrit; CRP = C-reactive protein; 
IPH = intact parathyroid hormone; URR = urea reduction ratio; Kt/V = fractional clearance index for urea.
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alcohol consumption, gender distribution, duration 
of hemodialysis, pre-hemodialysis body fat mass, 
white blood cell count, serum homocystine, adi-
ponectin, CRP, total cholesterol, triglyceride, calcium, 
phosphorous, calcium-phosphorous deposition, URR 
and Kt/V urea between patients with and without 
arterial stiffness.
Multivariate forward stepwise linear regression 
analysis of arterial stiffness showed that systolic 
blood pressure and age were independent predic-
tors of arterial stiffness in hemodialysis patients 
(R2 = 0.458); the results are presented in Table 4.
4. Discussion
The results of our study showed that age and systolic 
blood pressure were independent predictors of arte-
rial stiffness in hemodialysis patients and the inci-
dence of arterial stiffness was high in hemodialysis 
patients. The results were the same as age and systo-
lic blood pressure were significant factors associated 
with increased PWV in patients with diabetes with 
arterial stiffness [12].
The principal pathophysiological consequences 
of vascular alterations in ESRD include increased 
intima-media thickness, decreased arterial distensi-
bility and increased PWV that increase systolic blood 
pressure, left ventricular hypertrophy and altered 
coronary circulation [13]. These changes induce 
high cardiovascular mortality rate in individuals 
on dialysis [14]. After stratification for age, gender, 
race, and the presence or absence of diabetes, car-
diovascular death in dialysis patients is 10–20 times 
higher than in the general population [1]. Traditional 
cardiovascular risk factors identified in the general 
population include hypertension, diabetes mellitus, 
hyperlipidemia, tobacco use, and physical activity. 
In addition, some uremia-related risk factors, such 
as anemia, abnormalities in calcium phosphate bal-
ance, hyperhomocysteinemia, increased oxidative 
stress, and inflammatory vascular response, also 
contribute to the high incidence of cardiovascular 
disease in patients with uremia [4,15]. In addition 
to correlations between PWV and cardiovascular risk 
factors in patients with uremia, our results showed 
that age, systolic blood pressure, fasting glucose 
and anemia were associated with arterial stiffness in 
uremia. Increased CRP is a significant risk factor for 
cardiovascular events and death in the ESRD popu-
lation [16]. Adiponectin enhances insulin sensitivity 
and is inversely related to metabolic risk factors like 
glucose, triglyceride, and insulin in uremic patients, 
suggesting that this cytokine is a protective factor 
for atherosclerosis in patients with uremia [17]. Our 
results did not show a relationship between CRP and 
adiponectin with arterial stiffness in hemodialysis 
patients. This may be due to the small number of 
cases in this study, and further randomized studies 
are needed.
Aging is a risk factor for the development of arterial 
stiffness and vascular disease [18], and it is related 
to the upregulation of matrix metalloproteinase-2 in 
the aorta of humans [19]. The changes induced ves-
sel luminal dilation, medial thickening, elastic mem-
brane fragmentation, thickening of vascular intima 
and increased arterial stiffness [19]. Increased systo-
lic blood pressure and loss of elasticity in large arter-
ies in the elderly are considered a normative aging 
process of the arterial wall [20]. Elevated blood pres-
sure over time can also lead to vascular remodeling, 
hypertrophy, and hyperplasia that produce intrinsic 
arterial stiffening [20]. Annual rates of progression 
in PWV were higher in subjects treated for hyper-
tension than in normotensive subjects, suggesting 
accelerated progression of arterial stiffness among 
the hypertensive subjects [21]. Systolic blood pres-
sure rises as a result of arterial stiffness and early 
pulse wave reflection which is a major problem in 
hemodialysis patients [22]. Systolic blood pressure 
is a significant independent predictor of survival in 
hemodialysis patients [22]. Arterial stiffness is also 
more closely associated with ischemic heart disease 
in patients with type 2 diabetes mellitus [23]. Arterial 
stiffness was increased in patients who had diabetes 
and was increased further in a stepwise manner with 
the advanced stage of chronic renal failure or ure-
mia [12,24]. Uncorrected anemia will result in sym-
pathetic nervous system activation and decreases 
in systemic vascular resistance, contributing to the 
development of left ventricular hypertrophy, heart 
failure and increased arterial stiffness [25,26]. 
Epidemiologic studies have confirmed anemia to be 
a highly significant and independent risk factor for 
death and hospitalization in hemodialysis patients. 
Complementary cohort studies in dialysis patients 
demonstrated clear associations between ane-
mia and cardiovascular disease [27]. However, the 
results of our study showed that after multivariate 
forward stepwise linear regression analysis, systolic 
blood pressure and age were the major independ-
ent factors associated with increased PWV in uremia 
patients.
Table 4 — Multivariate stepwise linear regression 
analysis of arterial stiffness*
Items  β R2 R2 change p
SBP 0.008 0.307 0.307 < 0.001
Age (yr) 0.010 0.458 0.151 0.002
*Dependent variable: brachial-ankle pulse wave velocity; independ-
ent variable: age, hematocrit, systolic blood pressure (SBP) and fast-
ing glucose.
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Recent studies have revealed that patients with 
chronic renal failure show stepwise increases in 
the risk for cardiovascular disease and increased 
regional PWV in a stepwise manner at different 
stages of chronic renal failure [28,29]. Arterial stiff-
ness is a strong independent predictor of cardio-
vascular disease death in uremia patients and is an 
excellent predictor of survival in ESRD patients [2,3]. 
Early diagnosis of arterial stiffness with noninvasive 
techniques before the development of cardiovascu-
lar complications is important in patients with ure-
mia [10]. Guerin et al showed that ACE inhibitors 
(perindopril) decreased PWV and improved the sur-
vival rates of patients with uremia [30]. Fluvastatin 
reduced PWV and prevented further worsening of 
arterial biomechanics in diabetic uremic patients 
[31]. Further studies with large numbers of patients 
and long observation periods are needed to con-
firm the beneficial effects of ACE inhibitors or 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors on arterial stiffness in uremic 
patients.
There were some limitations to our study. First, this 
was a cross-sectional study. Therefore, the conclu-
sions must await further exploration of outcome stud-
ies and attempts at modifying PWV. Second, the case 
number was small. Third, history of drug use in this 
study is pending and the affects of the drugs on arte-
rial stiffness is unknown. Thus, further studies with 
larger numbers of patients and long follow-up periods 
are required to elucidate this complex relationship.
In conclusion, the results of our study showed that 
arterial stiffness was higher in hemodialysis patients. 
Systolic blood pressure and age were independent pre-
dictors of arterial stiffness in hemodialysis patients.
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